<DOC>
	<DOCNO>NCT00128778</DOCNO>
	<brief_summary>This randomize , prospective multicenter phase IV clinical trial , design phase III study . One hundred fifty-four woman ( 77 per treatment arm ) recruit study .</brief_summary>
	<brief_title>Maintenance Treatment With Liposomal Doxorubicin ( Caelyx ) Metastatic Breast Cancer Patients</brief_title>
	<detailed_description>The main variable time disease progression . All patient must treat first line induction chemotherapy , consist doxorubicin 75 mg/m2 , day 1 every 3 week , docetaxel , 100 mg/m2 , day 1 every 3 week . Both drug must administer sequentially . Patients previously treat anthracyclines must receive 2 course doxorubicin 4 course docetaxel . Otherwise , patient receive 3 course doxorubicin follow 3 course docetaxel . Patients complete response , partial response stable disease eligible GEICAM 2001-01 study . The investigator assume maintenance treatment Caelyx increase mean time progression 10 , 46 month ( observation ) 17 , 43 month . Expected difference mean time progression 6 , 97 month ( Hazard ratio = 0.6 ) . With alpha error 0.01 ( unilateral ) power 80 % , 77 patient per arm need , 154 patient total .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Written inform consent . Patients metastatic breast cancer respond first line induction chemotherapy treatment . Age : least 18 year old . Performance status ECOG 0 , 1 , 2 . Normal cardiac function , confirm leave ventricular ejection fraction ( LVEF ) . Hematology : leucocyte &gt; = 4 x 10^9/l ; neutrophil &gt; = 2.0 x 10^9/l ; platelet &gt; = 100 x 10^9/l ; hemoglobin &lt; = 10 g/dl . Hepatic function : total bilirubin &lt; 1 upper limit normal ( UNL ) ; ASAT ( SGOT ) ALAT ( SGPT ) &lt; 2.5 UNL ; alkaline phosphatase &lt; 5 UNL . Patients ASAT ( SGOT ) ALAT ( SGPT ) &gt; 1.5 UNL alkaline phosphatase &gt; 2.5 UNL eligible . Renal function : creatinine &lt; 175 mmol/l ( 2 mg/dl ) ; creatinine clearance &gt; 45 ml/min . Pregnant lactating patient . Previous cardiac dysfunction grade II high per New York Heart Association , along congestive cardiac failure . Hypersensitivity anthracyclines CremophorÂ® . Clinically significant hepatic dysfunction . Current uncontrolled infection . Mental confusion lack orientation . Any circumstance precluding adequate followup . Radiotherapy previous 4 week . Any concurrent neoplasm , except basal cell carcinoma situ carcinoma . Symptomatic metastasis brain . Previous radiotherapy radiate third haematopoietic centre . Males .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Metastases</keyword>
	<keyword>Maintenance treatment</keyword>
</DOC>